IDH1 and central nervous system cancer: While we could confirm that most LTS consisted of patients with IDH-mutant glioma and most STS had IDH-wildtype gliomas and thereby validate the current classification framework, there were outliers with unexpected prognosis based on their molecular background and DNA methylation profiles.